Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

57.30USD
4 Sep 2015
Change (% chg)

$-1.45 (-2.47%)
Prev Close
$58.75
Open
$58.08
Day's High
$58.48
Day's Low
$56.90
Volume
4,078,411
Avg. Vol
1,917,252
52-wk High
$70.54
52-wk Low
$47.54

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company's products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $95,547.91
Shares Outstanding(Mil.): 1,667.50
Dividend: 0.37
Yield (%): 2.58

Financials

  BMY.N Industry Sector
P/E (TTM): 53.59 35.80 35.95
EPS (TTM): 1.07 -- --
ROI: 7.39 15.54 14.99
ROE: 11.76 16.12 15.87
Search Stocks

Deals of the day- Mergers and acquisitions

Aug 31 - The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Monday:

31 Aug 2015

Bristol-Myers buys rights to acquire fibrosis drug developer

- Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.

31 Aug 2015

UPDATE 1-Bristol-Myers buys rights to acquire fibrosis drug developer

Aug 31 - Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.

31 Aug 2015

Bristol-Myers buys rights to fibrosis drug for up to $1.25 bln

Aug 31 - Drugmaker Bristol-Myers Squibb said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior Inc for up to $1.25 billion.

31 Aug 2015

AbbVie, Bristol-Myers get FDA nod for hep C treatments

- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

24 Jul 2015

CORRECTED-UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments

July 24 - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

24 Jul 2015

Bristol beats forecasts, raises profit view, shares jump

- Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.

23 Jul 2015

UPDATE 2-Bristol beats forecasts, raises profit view, shares jump

July 23 - Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.

23 Jul 2015

Bristol-Myers beats forecasts, raises full-year profit view

July 23 - Bristol-Myers Squibb Co reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.

23 Jul 2015

Bristol-Myers loses bid to revive drug distribution lawsuit

- A federal judge in Manhattan has rejected a last-ditch attempt by Bristol-Myers Squibb Co to save a lawsuit accusing Mylan Laboratories Ltd of breaching an agreement to distribute an AIDS drug in developing countries, refusing to reconsider his second order dismissing the case.

21 Jul 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $91.31 -1.33
Pfizer Inc. (PFE.N) $31.37 -0.52
Merck & Co., Inc. (MRK.N) $51.59 -1.06
Sanofi SA (SASY.PA) €87.17 -2.34
AstraZeneca plc (AZN.L) 4,181.50p -66.00
GlaxoSmithKline plc (GSK.L) 1,303.50p -35.00
Eli Lilly and Co (LLY.N) $80.32 -1.28

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks